South Korea Veterinary GMP Overhaul 2027: Four Major Changes and What They Mean

South Korea is rewriting the rulebook for how veterinary drugs get made. On July 30, the Ministry of Agriculture, Food and Rural Affairs (MAFRA) released a revised Veterinary Drug Handling Rules that raises the country’s Good Manufacturing Practice (GMP) standards. The new framework takes effect in 2027 and is set to be fully rolled out by 2035.

If you make, import, or plan to sell veterinary drugs in Korea, this is not a small tweak. It is a structural reset. The bar for quality assurance goes up, product-specific evaluations come in, and a re-inspection obligation appears that simply did not exist before.

Here is what changed, why it changed, and what it means for your business.

Why Korea decided to overhaul veterinary GMP

Korea has required GMP compliance for all veterinary drugs since 2004, so the system is not new. The trouble is that the old framework was built around dosage forms, not individual products.

Under the previous rules, a facility was judged by the type of preparation it produced, things like tablets, injections, or oral liquids. That worked on paper but left real gaps. Core GMP elements such as process validation and equipment qualification were never brought in systematically. For high-risk products like new chemical entities, injectables, and biologicals, judging quality by dosage form alone made it hard to guarantee consistent quality for each specific product.

Without validation, manufacturers could not objectively prove their processes reliably produced safe, effective product. It also held back efficiency, since plants had no standardized way to show they were in control of their own operations.

There is a strategic reason too. Korea has said it wants to join the Pharmaceutical Inspection Co-operation Scheme (PIC/S) by 2038, which would open clearer routes into European and U.S. markets. Bringing domestic GMP in line with international expectations is a necessary step toward that. The 2027 overhaul is the domestic half of a longer export play.

The four major changes

1. From facility-centered to product-centered classification

The old system split veterinary drugs into just two buckets: general veterinary drugs and biological products such as vaccines. The new framework expands this into six categories:

• Finished formulations
• Active pharmaceutical ingredients (APIs)
• Biological products
• Radiopharmaceuticals
• Medical high-pressure gases
• Blood products

The bigger shift is in the logic. Regulators used to ask what kind of facility was making the drug. Now they ask what specific product is being made and what it needs. Even inside the same building, different products must follow production and quality controls built for their own characteristics.

2. A product-specific GMP evaluation system

When a company applies for marketing authorization for a product, it now has to submit GMP data specific to that product. That means the production floor plan, facility and environmental monitoring data, validation documentation, and other production and quality files. Each category of veterinary drug follows its own manufacturing and quality control standards.

There is a small break built in. Facilities that already hold GMP approval can skip duplicate GMP filings when they apply to market a new product in the same dosage form, unless it is a new drug or a biological. That cuts administrative load without weakening oversight where it counts.

3. A three-year re-inspection cycle

Before, a manufacturing site got GMP approval once, at the time of its initial license, and was never required to be re-evaluated. That ends. From 2027, manufacturers must pass a full GMP re-assessment every three years.

For plants that have coasted on a decades-old approval, this adds a recurring compliance rhythm. Quality systems now have to be maintained all the time, not just proven once.

4. Phased rollout, with injectables first

MAFRA knows facility upgrades take time, so the new standards arrive in stages by dosage-form group:

• Injectables and infusion solutions come first. They carry the highest priority.
• External preparations and oral liquid formulations follow.
• Biological products and APIs come last.

The full upgrade runs from 2030 through 2035, giving manufacturers a staged runway to adapt. Injectables lead the way because they carry the most risk and the least tolerance for quality failure.

The timeline at a glance

• 2027: Revised Veterinary Drug Handling Rules take effect. The three-year re-inspection cycle begins.
• 2030 to 2035: Higher standards apply across the three dosage-form groups, injectables first.
• 2035: The upgrade is complete.
• 2038 (target): Korea aims to join PIC/S.

That is roughly ten years of transition for the domestic industry, and a permanently higher wall for anyone trying to get in.

What this means for international veterinary drug companies

For foreign manufacturers looking at the Korean market, the reform cuts both ways. A more transparent, internationally aligned GMP system makes the market more predictable and credible. At the same time, the practical bar for entry is rising.

Product-specific evaluations mean you cannot lean on a generic facility approval. You have to document, validate, and defend the quality of each individual product you want to sell. The new re-inspection cycle is an ongoing obligation, not a one-time gate. And because the rollout is phased, the standard your product faces depends on which group it lands in. Injectable makers should expect the earliest and strictest scrutiny.

Companies that start now, by mapping their portfolio against the six new categories, building validation dossiers, and planning for three-year re-assessments, will be far better placed than those who wait for the 2027 deadline to show up.

The bottom line

Korea’s veterinary GMP overhaul is both a domestic quality upgrade and a bid for more weight in the global animal health industry. From the 2027 launch to the 2035 finish line, the country is rebuilding its quality infrastructure around products rather than facilities, and around continuous oversight rather than a single approval.

For international players, the door to the Korean market is not closing. It now asks for a higher standard of proof. The time to build that proof is before 2027, not after.